Morningstar

Boston Scientific Corp BSX

Morningstar Rating
Unlock
Stock XNYS Rating as of
$42.60 −0.63 (1.46%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Competitive Pressure Bears Down on Boston Scientific's Key Growth Drivers

Debbie S. Wang

Boston Scientific has proved to be a fierce competitor among the three major cardiac device makers, with a record of meaningful innovation and impressive operational chops. Even a prolonged period of operational and management upheaval from 2006 to 2014 wasn't enough to permanently impair Boston's underlying business or the organization's ability to develop and commercialize new technology platforms. Under CEO Michael Mahoney, the firm has focused on introducing novel technology, accelerating growth, and leveraging its historically formidable sales and marketing resources.

Read Analysis

Price vs Fair Value

View History
BSX is trading at a LOCK|#%Hd%b# premium.
Price
$42.60
Fair Value
HKP
Uncertainty
LOCK|^tr$g
1-Star Price
LOCK|.f
5-Star Price
LOCK|.T<
Economic Moat
LOCK|KgYV&
Capital Allocation
LOCK|qZSSpB

Bulls Say, Bears Say

Bulls

Boston remains one of the top players when it comes to intellectual property in medtech, which bodes well for its ability to innovate enough to keep up with rivals.

Bears

Boston's coronary stent business is less moaty than its cardiac rhythm management segment.

Show More

News

View All

Articles & Videos

Trading Information

Previous Close Price
$43.23
Day Range
$41.94–43.44
52-Week Range
$41.94–105.65
Bid/Ask
$42.58 / $42.80
Shares Outstanding
1.45B
Market Cap
$61.74B
Volume/Avg
18M / 20M

Key Statistics

Price/Earnings (Normalized)
13.47
Price/Sales
3.07
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Core
Total Number of Employees
59,000
Website
https://www.bostonscientific.com

Competitors

Valuation

View More
Metric
BSX
MDT
ABT
Price/Earnings (Normalized)
 13.4715.2718.37
Price/Book Value
 2.512.203.27
Price/Sales
 3.072.963.62
Price/Cash Flow
 12.4612.4015.44
Price/Earnings
BSX
MDT
ABT

Financial Strength

Metric
BSX
MDT
ABT
Quick Ratio
 0.561.290.97
Current Ratio
 1.242.071.38
Interest Coverage
 11.5610.1210.40
Quick Ratio
BSX
MDT
ABT

Profitability

Metric
BSX
MDT
ABT
Return on Assets (Normalized)
 11.01%8.31%9.71%
Return on Equity (Normalized)
 19.82%15.59%17.95%
Return on Invested Capital (Normalized)
 14.09%10.57%13.03%
Return on Assets
BSX
MDT
ABT

Medical Devices Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
LOCK|Dx$$>dyLOCK|P>wc>$169B
 Medtronic PLC
MDT
LOCK|d%XH>nsLOCK|?d!>$110B
 Stryker Corp
SYK
LOCK|KpXSYNL$LOCK|tyZ$106B
 Edwards Lifesciences Corp
EW
LOCK|&@jmbVC?LOCK|@>RZ$49B
 DexCom Inc
DXCM
LOCK|Y^%Cc@?&LOCK|@grH$32B
 GE HealthCare Technologies Inc Common Stock
GEHC
LOCK|#m<Spt?LOCK|?#$29B
 Koninklijke Philips NV ADR
PHG
LOCK|?%LOCK|Nh$23B
 Steris PLC
STE
LOCK|qQQTs%KLOCK|T?!mh$20B
 Zimmer Biomet Holdings Inc
ZBH
LOCK|&RKB#yrLOCK|#?q$17B

Sponsor Center